Taylor and colleagues [1] examined the time course of gene expression profi le changes in estrogen (E2)-treated and E2 and tamoxifen-treated mouse xenografts. Th e authors pre sented three distinct categories of gene expression temporal profi les, each characterized by two sets of genes. Diff erentially expressed genes at some early time points following treatment were found to be prognostic of survival in clinical data sets, but not those identifi ed at other time points. Th is implies that the timing of the post-treatment sample for gene expression analysis will be critical for the development of prognostic and predictive biomarkers.
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Adjuvant endocrine treatment in estrogen receptorpositive (ER+) breast cancer patients reduces the risk of relapse and death from breast cancer [2] , but large numbers of patients still die of endocrine therapyresistant disease [3] . Researchers have therefore devoted intensive eff orts to identify molecular biomarkers to predict response to endocrine treatment and, in spite of the inherent heterogeneity among ER+ breast tumors, gene expression signatures have been successfully developed [4] [5] [6] . However, the existing signatures are based on gene expression information in a single baseline tumor sample that may not capture all the biological information necessary for predictive accuracy. Clinically, patients fall into three broad categories, continuously responding, continuously resistant, and a substantial group of patients with an initial response followed by a transition at varying rates to an acquired resistance phenotype. Late recurrence in resistant patients might be avoided if these tumors could be identifi ed early, before the onset of clinical resistance, and subjected to an eff ective salvage intervention. Th erefore, the discovery of gene signatures diff erentiating the three response groups logically requires the identifi cation of temporal changes in gene expression along the treatment course. Th e paper by Taylor and colleagues [1] illustrates this principle.
Microarray gene expression data were used by Taylor and colleagues [1] for discovery and validation of gene expression signatures. Overall, the paper is a good example of the practice of microarray data analysis. Raw data were deposited in CaArray [7] to be available to the public, which encourages research reproducibility. After the gene discovery process, validation in multiple independent public datasets was carried out. An important caveat of this aspect of the paper is that these datasets are not particularly suitable to assess the primary hypothesis because all these studies report only baseline array gene expression levels -not treatment-induced changes. Th e true test of the approach would be to compare the prognostic information in the baseline sample with posttreatment samples taken at diff erent time points from the same patient. Moreover, signifi cance of potential therapyresponse gene signatures in treated versus untreated patient cohorts should be interpreted with caution.
Th e paper also identifi es areas for methodological improvement. Th e data analysis is limited to two-class comparison at each individual time point, which neglects time dependency in gene expression profi ling. Th e definition of the six sets of genes is subjectively deter mined Abstract Microarray data have been widely utilized to discover biomarkers predictive of response to endocrine therapy in estrogen receptor-positive breast cancer. Typically, these data have focused on analyses conducted on the diagnostic specimen. However, dynamic temporal changes in gene expression associated with treatment may deliver signifi cant improvements to the current generation of predictive models. We present and discuss some statistical issues relevant to the paper by Taylor and colleagues, who conducted studies to model the prognostic potential of gene expression changes that occur after endocrine treatment.
by known pathways. Ideally, the continuous longitudinal gene expression profi ling would be better analyzed as a whole by functional data analysis techniques [8, 9] . Rather than traditional cluster analysis [10] , cluster tools designed specifi cally for time course gene expression data, such as CAGED (Cluster Analysis of Gene Expression Dynamics) [11] , would probably serve better. Furthermore, the class comparison in the paper depends on fold change alone, a common error in the analysis of microarray data [12] . Fold change is easy to calculate and understand; however, it is a single ratio without consideration of variability. Use of fold change usually leads to high false positives since small changes in genes with low expression levels can lead to large fold change. Th e hierarchical algorithm is applied to public microarray data in the paper to divide samples into low and high expression groups. Th e use of unsupervised clustering for class prediction is very subjective [12] . Th e two-color microarray design was used while the authors commented on the possible benefi ts of using a one-color design. Th e two-color with common reference design has been the most widely used in microarray experiments for its ease of implementation and analysis. Th e one-color design has recently emerged to be a favorite because of its simplicity and fl exibility after confi rmation of comparative data quality to its two-color counterpart. However, the two-color design is still reported to exhibit a small advantage in detecting diff erential genes, especially for genes of small fold changes [13] .
In their paper, Taylor and colleagues speculated that the 'early/transient' expression changes are the causative events for tumor inhibition. Th is might be true but needs to be investigated more carefully in future studies. Meanwhile, it is important to acknowledge the fact that some patients who respond initially and exhibit the early/ transient expression change may acquire resistance gradually. It will be challenging to pick these patients out for individualized treatment planning as the critical changes may take place only after months or years of endocrine therapy exposure.
In conclusion, we fully agree on the importance of investigating temporal gene expression profi ling for prediction of treatment response. More well-planned studies will be required for insights into these complicated data sets and variability in response to treatment will be an important consideration. Th e task of obtaining consecutive gene expression profi ling at multiple time points remains a challenging prospect but might be feasible in well planned neoadjuvant endocrine therapy studies where patients might be triaged to alternative therapy if an unresponsive gene expression profi le emerged, even when the patient was in response clinically.
Abbreviations ER = estrogen receptor.
